3-Benzyl-2-(trifluoromethyl)imidazo[1,2-a]pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 3-Benzyl-2-(trifluoromethyl)imidazo[1,2-a]pyridine
• 英文别名: 3-benzyl-2-(trifluoromethyl)imidazo[1,2-a]pyridine
• 化学式: C₁₅H₁₁F₃N₂
• 分子量: 276.26
• InChiKey: AENRBWIPRMDPQL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  17.3
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• BRIVARACETAM FOR IMPROVING COGNITIVE FUNCTION
  申请人：The Johns Hopkins University

  公开号：EP3827820A1

  公开（公告）日：2021-06-02

  This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A), alone or in combination with valproate, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease, autism, compulsive behavior, and substance addiction.

  本发明涉及治疗与中枢神经系统（CNS）疾病相关的认知障碍的方法和组合物。特别是，本发明涉及突触小泡糖蛋白 2A (SV2A)抑制剂单独或与丙戊酸钠联合用于治疗与中枢神经系统 (CNS) 疾病相关的认知功能损害，需要治疗或有治疗风险的受试者包括但不限于有年龄相关认知功能损害、轻度认知功能损害 (MCI) 或有此风险的受试者、老年痴呆症、阿尔茨海默病（AD）、前驱 AD、创伤后应激障碍（PTSD）、精神分裂症、双相情感障碍、肌萎缩性脊髓侧索硬化症、癌症治疗相关认知障碍、智力迟钝、帕金森病、自闭症、强迫行为和药物成瘾。
• METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
  申请人：The Johns Hopkins University

  公开号：EP2919788A1

  公开（公告）日：2015-09-23
• METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
  申请人：Agenebio, Inc.

  公开号：EP2968220A1

  公开（公告）日：2016-01-20
• METHODS AND COMPOSITONS FOR IMPROVING COGNITIVE FUNCTION
  申请人：The Johns Hopkins University

  公开号：EP2968257A1

  公开（公告）日：2016-01-20
• [EN] METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA<br/>[FR] MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT DE LA SCHIZOPHRÉNIE
  申请人：UNIV JOHNS HOPKINS

  公开号：WO2014078568A1

  公开（公告）日：2014-05-22

  The invention relates to methods and compositions for treating schizophrenia or bipolar disorder (in particular, mania) by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an antipsychotic or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs, and prodrugs thereof. The methods and the compositions can be used for treating one or more positive and/or negative symptoms, as well as cognitive impairment, associated with schizophrenia or bipolar disorder (in particular, mania).